Cencora, Inc. (NYSE:COR - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q4 2024 earnings estimates for shares of Cencora in a report issued on Monday, October 7th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $3.23 per share for the quarter, down from their previous estimate of $3.24. The consensus estimate for Cencora's current full-year earnings is $13.63 per share. Leerink Partnrs also issued estimates for Cencora's FY2027 earnings at $18.32 EPS and FY2028 earnings at $20.10 EPS.
Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm had revenue of $74.20 billion during the quarter, compared to analysts' expectations of $73.32 billion. During the same quarter last year, the business posted $2.92 earnings per share. The firm's revenue was up 10.8% on a year-over-year basis.
Several other research firms also recently commented on COR. Robert W. Baird dropped their price objective on shares of Cencora from $287.00 to $283.00 and set an "outperform" rating for the company in a report on Friday, September 6th. Wells Fargo & Company increased their price target on Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. raised their price target on Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a report on Wednesday, August 21st. Bank of America reaffirmed a "neutral" rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Finally, Leerink Partners cut their target price on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a report on Monday. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Cencora has an average rating of "Moderate Buy" and an average price target of $259.44.
View Our Latest Research Report on COR
Cencora Price Performance
Shares of COR stock traded up $0.38 during mid-day trading on Wednesday, hitting $221.19. The company had a trading volume of 1,295,002 shares, compared to its average volume of 1,416,082. The company has a market capitalization of $44.12 billion, a P/E ratio of 24.20, a P/E/G ratio of 1.58 and a beta of 0.44. The stock's 50 day moving average price is $233.91 and its 200-day moving average price is $231.68. Cencora has a 52-week low of $182.75 and a 52-week high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.
Institutional Investors Weigh In On Cencora
Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. purchased a new stake in shares of Cencora during the 4th quarter valued at $4,212,508,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Cencora during the first quarter valued at $2,183,619,000. JPMorgan Chase & Co. acquired a new position in shares of Cencora in the 1st quarter valued at $1,199,695,000. Boston Partners purchased a new position in Cencora in the 1st quarter worth $1,001,269,000. Finally, Capital Research Global Investors acquired a new stake in Cencora during the 1st quarter worth about $650,424,000. Institutional investors own 97.52% of the company's stock.
Insider Buying and Selling
In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the firm's stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares of the company's stock, valued at approximately $4,806,388,800. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business's stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,473 shares of the firm's stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,450,399 shares of company stock valued at $1,070,392,799 in the last ninety days. 15.80% of the stock is owned by company insiders.
Cencora Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were issued a dividend of $0.51 per share. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 annualized dividend and a yield of 0.92%. Cencora's payout ratio is 22.32%.
About Cencora
(
Get Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Recommended Stories
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
